The__O impact__O of__O the__O Sheffield__B-MISC chemoinformatics__O work__O in__O terms__O of__O increasing__O economic__O prosperity__O for__O the__O pharmaceutical__O industry__O and__O increasing__O the__O range__O of__O medicines__O available__O to__O patients__O has__O been__O two-fold:__O by__O means__O of__O software__O developed__O in__O Sheffield__B-LOC and__O then__O distributed__O to__O industry;__O and__O by__O means__O of__O extensive__O industrial__O adoption__O of__O algorithms__O and__O methods__O published__O by__O the__O group__O in__O the__O open__O literature.__O
The__O reach__O of__O the__O work__O is__O demonstrated__O by__O its__O current__O use__O throughout__O the__O pharmaceutical__O industry__O and__O the__O significance__O by__O its__O role__O in__O helping__O to__O discover__O new__O drugs__O that__O can__O benefit__O patients__O throughout__O the__O world.__O
GOLD__O has__O been__O distributed__O by__O CCDC__B-ORG since__O 1998__O and__O is__O currently__O used__O for__O pharmaceutical__O research__O in__O over__O 50__O different__O countries:__O "For__O many__O years,__O GOLD__O has__O been__O one__O of__O the__O top__O two__O protein-ligand__O docking__O programs__O for__O industrial__O and__O academic__O research__O in__O drug__O discovery,__O and__O is__O used__O by__O around__O 60__O major__O pharmaceutical__O companies__O and__O more__O than__O 600__O Universities__B-ORG worldwide"__O [S2];__B-ORG "My__O group__O of__O 18__O modellers__O and__O chemoinformaticians__O are__O actively__O involved__O in__O the__O support__O of__O many__O drug__O discovery__O projects;__O our__O work__O has__O led__O to__O the__O discovery__O of__O several__O novel__O chemical__O entities__O now__O in__O the__O clinic__O or__O on__O the__O market.__O
One__O of__O the__O tasks__O we__O perform__O is__O virtual__O screening__O of__O large__O databases__O of__O chemical__O structure,__O and__O for__O that__O purpose__O we__O regularly__O use__O GOLD__O as__O the__O tool__O of__O choice"__O [S3].__O
GASP__O has__O been__O distributed__O by__O Tripos__O since__O 1996,__O with__O an__O enhanced__O version__O available__O since__O 2003,__O and__O GALAHAD__B-ORG has__O been__O distributed__O by__O them__O since__O 2005.__O
These__O three__O products__O have__O been__O very__O successful__O commercially,__O with__O total__O sales__O to__O date__O of__O ca.__O
&#163;7__O million__O and__O with__O royalties__O to__O the__O University__B-ORG of__I-ORG Sheffield__I-ORG of__I-ORG ca.__I-ORG
&#163;900K__O (&#163;82K__O in__O 2008-12).__O
The__O software__O licensees__O include__O many__O of__O the__O world's__O leading__O chemical__O companies,__O with,__O e.g.,__O GASP__B-ORG and__O GALAHAD__B-ORG users__O including__O Amgen,__B-PER Bayer,__I-PER Boehringer__B-PER Ingelheim,__I-PER Bristol-Myers__O Squibb,__B-PER DuPont,__I-PER Eli__I-LOC Lilly,__I-LOC Genentech,__I-LOC GSK,__I-LOC Novo__I-LOC Nordisk,__I-LOC Sanofi__I-PER Aventis__I-PER and__O Syngenta__B-LOC inter__O alia.__O
License__O holders__O such__O as__O these__O have__O made__O very__O extensive__O use__O of__O the__O software,__O as__O demonstrated__O by__O published__O accounts__O in__O the__O scientific__O literature__O of__O the__O use__O of__O GALAHAD,__B-ORG GASP__I-ORG and__O GOLD__O in__O companies'__O internal__O drug-discovery__O projects.__O
WoS__O searches__O in__O October__O 2013__O for__O the__O six__O references__O listed__O in__O Section__B-ORG 3__O reveals__O over__O 250__O citations__O to__O this__O research__O by__O industrial__O companies__O in__O 2008-13.__O
For__O example,__O articles__O in__O two__O leading__O medicinal__O chemistry__O journals__O (Journal__B-ORG of__I-ORG Medicinal__I-ORG Chemistry__I-ORG (IF=5.38)__I-ORG and__O Bioorganic__B-ORG and__O Medicinal__B-ORG Chemistry__I-ORG (IF=3.15))__I-ORG describe__O the__O use__O of__O the__O Sheffield__B-MISC software__O by__O world-leading__O pharmaceutical__O companies__O to__O support__O research__O in__O cancer__O (Genentech),__B-MISC heart__O disease__O (Pfizer__B-ORG and__O Proctor__B-ORG &amp;__I-ORG Gamble),__I-ORG cellular__O signalling__O (GSK),__B-ORG cognitive__O impairment__O such__O as__O schizophrenia__O and__O Alzheimer's__B-PER (Abbott),__I-PER and__O obesity__O (Takeda)__B-ORG inter__O alia.__O
The__O impact__O of__O the__O Sheffield__B-MISC work__O is__O much__O broader__O than__O just__O the__O three__O specific__O commercial__O products,__O in__O that__O techniques__O described__O by__O the__O Sheffield__B-PER group__O in__O the__O open__O literature__O have__O been__O widely__O adopted,__O as__O evidenced__O both__O by__O literature__O citation__O and__O by__O incorporation__O in__O software__O that__O is__O used__O around__O the__O world__O on__O a__O daily__O basis.__O
For__O example:__O "We__O also__O follow__O the__O work__O of__O the__O Sheffield__B-MISC group__O keenly__O and__O we__O have__O adopted__O some__O of__O their__O ideas__O on__O data__O fusion__O techniques__O and__O multi-objective__O optimization__O into__O our__O own__O code;__O we__O have__O done__O this__O more__O with__O the__O research__O coming__O out__O of__O this__O department__O than__O we__O have__O with__O any__O other__O academic__O cheminformatics__O group__O in__O Europe__B-LOC "__O [S3];__B-ORG "Sheffield__I-ORG research__O has__O been__O at__O the__O heart__O of__O all__O the__O commonly__O used,__O indispensable__O systems__O for__O handling__O chemical__O reactions,__O and__O 2D,__O 3D__O and__O generic__O chemical__O structures__O in__O industry.....Very__O few__O universities__O worldwide__O are__O capable__O of__O addressing__O the__O "virtual__O R&amp;D"__B-ORG problem;__O Sheffield__B-ORG is__I-ORG the__O leader"__O [S4].__O
